Frozen Tumor Organoid Panels for Rapid Multi-Organoid Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to efficiently culture and evaluate various tumor organoids simultaneously due to differences in growth rates, limiting effective drug screening and mass screening of anticancer drugs.
Innovation Solution
A method is developed to culture tumor organoids from cancer patients, manufacture them into a panel, freeze, and combine them after thawing, allowing for the creation of a customized tumor organoid panel that can be used for rapid anticancer drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If various tumor organoids are cultured simultaneously for drug evaluation, then comprehensive drug screening can be performed, but the different growth rates of tumor organoids make it difficult to culture and evaluate them together
Solution Approach 1:
The patent segments the tumor organoid evaluation process by creating individual frozen columns for each organoid type, which can then be independently stored and combined as needed. This allows different organoid types with different growth rates to be prepared separately and evaluated together without interference.
Solution Approach 2:
The patent applies preliminary action by freezing and storing tumor organoid columns before actual drug evaluation. This pre-preparation allows researchers to have ready-to-use organoid panels that can be quickly thawed and evaluated, eliminating the need to culture different growth-rate organoids simultaneously from scratch.
2Productivity
If tumor organoids are frozen to enable storage and later use, then mass screening becomes possible, but freezing may reduce organoid survival rate
Solution Approach 1:
The patent optimizes freezing parameters including temperature, freezing rate, and storage conditions to minimize damage to tumor organoids. By carefully controlling these parameters, the method achieves high survival rates while enabling long-term storage and mass screening capabilities.
3Measurement precision
If tumor organoids are cultured to appropriate size for evaluation, then accurate drug screening can be performed, but it takes time to reach optimal size
Solution Approach 1:
The patent performs preliminary culturing of tumor organoids to reach optimal evaluation size before freezing. This pre-culturing step ensures that when the frozen organoids are thawed for drug screening, they are already at the appropriate size and developmental stage for accurate evaluation, eliminating the need for extended culture periods during the actual screening process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables simultaneous evaluation of various tumor organoids, increases survival rates, and allows for rapid drug evaluation, making it effective for anticancer drug screening.
Implementation Method 1
freezing the manufactured tumor organoid panel
Data Source
AI summary
Provided is a method for making various organoid combinations by selecting frozen tumor organoid columns on the basis of genetic information, and analyzing drugs by using same. Particularly, the present invention relates to: a method for manufacturing a customized tumor organoid panel in which tumor organoids are frozen, thawed and stabilized in a 96-well strip plate in sizes suitable for drug evaluation, and then various tumor organoids are combined such that drugs can be rapidly mass-screened; and an anti-cancer drug screening system using the panel manufactured by the method. If drugs are evaluated using the customized tumor organoid panel, according to the present invention, the difficulty of simultaneous evaluation, caused by a difference in tumor organoid growth rates, can be solved, and evaluation can be carried out using various tumor organoids, and thus mass screening is possible.